Shaily Engineering Plastics Limited has informed the Exchange about Investor Presentation
SHAILY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shaily Engineering Plastics reported strong Q3FY26 results with consolidated revenue up 27% YoY to ₹250.5 Cr and 9MFY26 revenue up 32% to ₹753.8 Cr, driven by a 139% surge in healthcare segment. EBITDA grew 43% in Q3 to ₹66.4 Cr with margins expanding 310 bps to 26.5%, while 9MFY26 EBITDA margins jumped 730 bps to 29.0%. Profit after tax more than doubled in 9MFY26 to ₹129.8 Cr (+101%), and Cash PAT grew 73% to ₹165.7 Cr. The company announced a new Abu Dhabi facility for medical devices (AED 130-150 million investment, ~75 million pen injectors annual capacity, operational by Q4 FY28) and appointed Mr. Joe Kam as COO (Healthcare) effective March 2026. Capital efficiency improved sharply with RoCE rising to 38.4% and RoE to 29.1%.
Strong margin expansion and healthcare-led growth signal improving profitability, though the Abu Dhabi capex and capacity additions suggest near-term investment pressure. Credit rating reaffirmed at CARE A+ with stable outlook supports financial flexibility. Positive for shareholders given broad-based growth, improving returns, and strategic expansion into high-growth drug delivery segment.